C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

AstraZeneca

Status: Completed

Conditions: Cardiovascular Risk

Study type: Observational

Funder types: Industry

Identifiers

NCT00921752

NIS-CHU-DUM-2009/1

Details and patient eligibility

About

To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients at high cardiovascular risk according to Framingham or SCORE rates

Exclusion criteria

• Not eligible for lipid or statin therapy
• Intolerance to therapy
• Patients at low or intermediate CV risk

Trial design

1,500 participants in 1 patient group

Patients at high cardiovascular risk